ロード中...
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
BACKGROUND: Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic cancer patients achieved stable disease. PATIENTS AND METHODS: We conducted a multi-center phase II tri...
保存先:
| 出版年: | Invest New Drugs |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4319645/ https://ncbi.nlm.nih.gov/pubmed/20803052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9526-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|